$4.18
00.00%
Last update: 4:00 PM
15 minutes delayed
Comments
Loading...
Boundless Bio
BOLDNASDAQ
Latest news for Boundless Bio (NASDAQ:BOLD) Stock
Boundless Bio Stock (NASDAQ: BOLD)
Categories: All
Monday, April 22, 2024
Thursday, April 11, 2024
Monday, April 08, 2024
Thursday, March 28, 2024
Wednesday, March 27, 2024
Sunday, March 24, 2024
Tuesday, January 07, 2020
Friday, December 27, 2019
Thursday, December 12, 2019
Wednesday, December 11, 2019
Tuesday, December 10, 2019
Monday, December 09, 2019
Friday, December 06, 2019
Thursday, December 05, 2019
Wednesday, December 04, 2019
- Stocks That Hit 52-Week Highs On Wednesday
- Benzinga's Top Upgrades, Downgrades For December 4, 2019
- Chardan Capital Downgrades Audentes Therapeutics to Neutral, Announces $60 Price Target
- The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug
- SVB Leerink Downgrades Audentes Therapeutics to Market Perform
- 63 Biggest Movers From Yesterday
Tuesday, December 03, 2019
- Mid-Afternoon Market Update: DarioHealth Jumps On Walmart Distribution Deal; Cara Therapeutics Shares Plummet
- 40 Stocks Moving In Tuesday's Mid-Day Session
- Mid-Day Market Update: Audentes Therapeutics Climbs On Acquisition News; ASLAN Pharmaceuticals Shares Slide
- The Gene Therapy Names Moving On The Audentes Buyout Deal
- PreMarket Prep Recap: Red On The Screen And Looking For More
- Japan's Astellas To Buy Gene Therapy Company Audentes For $3B Cash
- Stocks That Hit 52-Week Highs On Tuesday
- Mid-Morning Market Update: Markets Open Lower; Cleveland-Cliffs To Acquire AK Steel For $3.36/Share
- Benzinga's Top Upgrades, Downgrades For December 3, 2019
- BMO Capital Downgrades Audentes Therapeutics to Market Perform, Raises Price Target to $60
- 10 Biggest Price Target Changes For Tuesday
- The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial
- Audentes Therapeutics shares are trading high...
- 19 Healthcare Stocks Moving In Tuesday's Pre-Market Session
- 22 Stocks Moving in Tuesday's Pre-Market Session
- HC Wainwright & Co. Downgrades Audentes Therapeutics to Neutral, Announces $60 Price Target
- Wedbush Downgrades Audentes Therapeutics to N...
- Raymond James Downgrades Audentes Therapeutics to Market Perform
- A Peek Into The Markets: US Stock Futures Down; Dow Futures Fall Over 100 Points
- Piper Jaffray Downgrades Audentes Therapeutics to Neutral, Raises Price Target to $60
- Baird Upgrades Audentes Therapeutics to Neutral
- Guggenheim Downgrades Audentes Therapeutics to Neutral
- Citigroup Upgrades Audentes Therapeutics to Neutral, Raises Price Target to $60